The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2016Electrical Stimulation of the Brain as Parkinson's Disease Treatment
Study Rationale:
Depression is a common non-motor symptom associated with Parkinson's disease (PD), and impulse control disorders (ICDs) are behaviors that may arise with use of certain PD medications... -
Research Grant, 2016Registry for the Advancement of Deep Brain Stimulation Therapy in Parkinson's Disease (RAD-PD)
Study Rationale:
Deep brain stimulation (DBS) is a surgical treatment for Parkinson's disease (PD) that may benefit those who experience motor complications, such as "off" periods and/or dyskinesia... -
Access to Data and Biospecimens, 2016MicroRNAs as biomarkers of the prodromal stage of Parkinson disease’
Study Rationale:
MicroRNAs (miRNAs) are small regulatory RNAs controlling gene expression. We have recently reported reduced miRNAs levels in serum from Parkinson disease (PD) patients, and also from...
-
Target Advancement Program, 2016Studying Monocyte Entry into the Brain in Alpha-synuclein-induced Parkinson's Disease
Study Rationale:
Alpha-synuclein is a sticky protein that clumps in the brains of people with Parkinson's disease (PD). In pre-clinical models, alpha-synuclein clumps attract scores of CCR2-positive... -
Research Grant, 2016Patient-Carer-Provider Communication about the Impact of Motor and Non-motor Fluctuations
Study Rationale:
Temporary periods of poor mobility and other symptoms (OFF periods) are common in Parkinson’s disease and are associated with poorer quality of life. OFF symptoms are complex, with... -
Biomarker Development, 2015Development of Novel, Small Molecule Compounds as PET Tracers for Synucleinopathies
Study Rationale:
Our project aims to develop a brain imaging agent for alpha-synuclein, a key protein involved in Parkinson’s disease (PD) pathology. Such an agent will help (i) diagnose PD earlier,...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.